Single-cell characterization of macrophages in uveal melanoma uncovers transcriptionally heterogeneous subsets conferring poor prognosis and aggressive behavior.
Journal
Experimental & molecular medicine
ISSN: 2092-6413
Titre abrégé: Exp Mol Med
Pays: United States
ID NLM: 9607880
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
09
09
2022
accepted:
25
07
2023
revised:
21
07
2023
medline:
4
12
2023
pubmed:
1
11
2023
entrez:
1
11
2023
Statut:
ppublish
Résumé
Uveal melanoma (UM) is the most frequent primary intraocular malignancy with high metastatic potential and poor prognosis. Macrophages represent one of the most abundant infiltrating immune cells with diverse functions in cancers. However, the cellular heterogeneity and functional diversity of macrophages in UM remain largely unexplored. In this study, we analyzed 63,264 single-cell transcriptomes from 11 UM patients and identified four transcriptionally distinct macrophage subsets (termed MΦ-C1 to MΦ-C4). Among them, we found that MΦ-C4 exhibited relatively low expression of both M1 and M2 signature genes, loss of inflammatory pathways and antigen presentation, instead demonstrating enhanced signaling for proliferation, mitochondrial functions and metabolism. We quantified the infiltration abundance of MΦ-C4 from single-cell and bulk transcriptomes across five cohorts and found that increased MΦ-C4 infiltration was relevant to aggressive behaviors and may serve as an independent prognostic indicator for poor outcomes. We propose a novel subtyping scheme based on macrophages by integrating the transcriptional signatures of MΦ-C4 and machine learning to stratify patients into MΦ-C4-enriched or MΦ-C4-depleted subtypes. These two subtypes showed significantly different clinical outcomes and were validated through bulk RNA sequencing and immunofluorescence assays in both public multicenter cohorts and our in-house cohort. Following further translational investigation, our findings highlight a potential therapeutic strategy of targeting macrophage subsets to control metastatic disease and consistently improve the outcome of patients with UM.
Identifiants
pubmed: 37907747
doi: 10.1038/s12276-023-01115-9
pii: 10.1038/s12276-023-01115-9
pmc: PMC10689813
doi:
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2433-2444Informations de copyright
© 2023. The Author(s).
Références
Mod Pathol. 2018 Feb;31(2):214-234
pubmed: 29192647
PLoS One. 2016 Oct 20;11(10):e0164292
pubmed: 27764126
J Exp Clin Cancer Res. 2021 May 4;40(1):154
pubmed: 33947438
J Immunother Cancer. 2022 Feb;10(2):
pubmed: 35121646
J Pathol. 2019 Apr;247(5):539-551
pubmed: 30511391
Genome Biol. 2019 Dec 23;20(1):296
pubmed: 31870423
Comput Struct Biotechnol J. 2022 Jun 16;20:3182-3194
pubmed: 35782742
Nat Rev Dis Primers. 2020 Apr 9;6(1):24
pubmed: 32273508
Nat Rev Clin Oncol. 2022 Jun;19(6):402-421
pubmed: 35354979
EMBO J. 2003 Oct 15;22(20):5323-35
pubmed: 14532106
Cancer Commun (Lond). 2022 Jul;42(7):587-608
pubmed: 35642770
Signal Transduct Target Ther. 2020 Aug 25;5(1):166
pubmed: 32843638
Exp Eye Res. 2020 Jul;196:108069
pubmed: 32439398
Pathol Oncol Res. 2020 Jul;26(3):1451-1458
pubmed: 31428993
Cell. 2021 Feb 4;184(3):792-809.e23
pubmed: 33545035
Nat Commun. 2020 Apr 20;11(1):1894
pubmed: 32313009
PLoS One. 2012;7(1):e29989
pubmed: 22267972
Ther Adv Med Oncol. 2018 Feb 21;10:1758834018757175
pubmed: 29497459
Cancer Cell. 2017 Aug 14;32(2):204-220.e15
pubmed: 28810145
Trends Immunol. 2022 Jul;43(7):546-563
pubmed: 35690521
OMICS. 2012 May;16(5):284-7
pubmed: 22455463
Nat Rev Cancer. 2022 Feb;22(2):68-69
pubmed: 34880443
Nat Methods. 2019 Dec;16(12):1289-1296
pubmed: 31740819
Cell. 2021 Jun 24;184(13):3573-3587.e29
pubmed: 34062119
Genome Med. 2021 May 19;13(1):88
pubmed: 34011400
Science. 2020 Jan 24;367(6476):405-411
pubmed: 31974247
Eur Rev Med Pharmacol Sci. 2018 May;22(9):2580-2587
pubmed: 29771443
PLoS One. 2010 Feb 02;5(2):e9020
pubmed: 20126307
Adv Sci (Weinh). 2022 Apr;9(12):e2103675
pubmed: 35112806
J Immunother Cancer. 2020 Nov;8(2):
pubmed: 33203661
Nat Methods. 2017 Nov;14(11):1083-1086
pubmed: 28991892
Nat Commun. 2020 Jan 24;11(1):496
pubmed: 31980621
NPJ Syst Biol Appl. 2022 May 24;8(1):18
pubmed: 35610253
Brief Bioinform. 2019 Mar 25;20(2):572-584
pubmed: 29659698
Brief Bioinform. 2021 Jul 20;22(4):
pubmed: 33367533
Lab Invest. 2023 Mar;103(3):100022
pubmed: 36925204
Nat Med. 2018 May;24(5):541-550
pubmed: 29686425
Exp Ther Med. 2021 Dec;22(6):1428
pubmed: 34707709
J Exp Clin Cancer Res. 2016 Jul 04;35(1):108
pubmed: 27377902
Invest Ophthalmol Vis Sci. 2011 Feb 03;52(2):643-50
pubmed: 20811059
NPJ Genom Med. 2021 Aug 16;6(1):70
pubmed: 34400647
J BUON. 2017 May-Jun;22(3):766-770
pubmed: 28730787
Nucleic Acids Res. 2019 Jan 8;47(D1):D721-D728
pubmed: 30289549
JAMA Ophthalmol. 2018 Sep 1;136(9):981-986
pubmed: 29955797
Cancer Res. 2011 Feb 1;71(3):666-74
pubmed: 21135111
Eye (Lond). 2017 Feb;31(2):241-257
pubmed: 27911450
Oncol Lett. 2019 Jan;17(1):314-322
pubmed: 30655769
Expert Rev Ophthalmol. 2011 Aug;6(4):405-407
pubmed: 22003361
J Immunol. 2000 Jul 15;165(2):710-5
pubmed: 10878343
J Adv Res. 2023 Feb;44:149-160
pubmed: 36725186
BMC Bioinformatics. 2013 Jan 16;14:7
pubmed: 23323831
Nat Biotechnol. 2014 Apr;32(4):381-386
pubmed: 24658644
J Innate Immun. 2012;4(5-6):454-62
pubmed: 22302072
Nat Rev Urol. 2017 Nov;14(11):639
pubmed: 28994827
Immunol Rev. 2017 Nov;280(1):102-111
pubmed: 29027220
Nat Biotechnol. 2022 Nov;40(11):1644-1653
pubmed: 35668323
Biochim Biophys Acta. 2016 Mar;1863(3):427-437
pubmed: 26264495
Clin Ophthalmol. 2017 Jan 31;11:279-289
pubmed: 28203054
Cancer Res. 2004 Oct 15;64(20):7205-9
pubmed: 15492234
Am J Pathol. 2006 Oct;169(4):1376-89
pubmed: 17003493
Elife. 2021 Jan 08;10:
pubmed: 33416496